{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:47:51Z","timestamp":1791431271550,"version":"4.3.3"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHS-N-260-2005-00007-C"],"award-info":[{"award-number":["HHS-N-260-2005-00007-C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["N01-EY-5-0007"],"award-info":[{"award-number":["N01-EY-5-0007"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000063","name":"Office of Dietary Supplements","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000064","name":"National Center for Complementary and Alternative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007015","name":"University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.oret.2020.09.025","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T05:02:30Z","timestamp":1602306150000},"page":"23-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Principal Cause of Poor Visual Acuity after Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"5","author":[{"given":"Chinwenwa U.","family":"Okeagu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2829-4042","authenticated-orcid":false,"given":"Elvira","family":"Agr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitha","family":"Domalpally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiarnan D.L.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2020.09.025_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev-genom-090413-025610","article-title":"Age-related macular degeneration: genetics and biology coming together","volume":"15","author":"Fritsche","year":"2014","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.oret.2020.09.025_bib2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/eye.2015.288","article-title":"Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013","volume":"30","author":"Quartilho","year":"2016","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2020.09.025_bib3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2020.09.025_bib4","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group","author":"Spaide","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib5","article-title":"Consensus definition for atrophy associated with age-related macular degeneration on OCT: Classification of Atrophy report 3","author":"Sadda","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib6","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.ophtha.2018.05.028","article-title":"Progression of geographic atrophy in age-related macular degeneration: AREDS2 report number 16","volume":"125","author":"Keenan","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib7","article-title":"Incidence of macular atrophy after untreated neovascular age-related macular degeneration: Age-Related Eye Disease Study report 40","author":"Christakis","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","article-title":"The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib9","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2020.09.025_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib11","article-title":"Visual acuity outcomes after anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: Age-Related Eye Disease Study 2 report number 19","author":"Keenan","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2020.09.025_bib12","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib13","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib14","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2020.09.025_bib15","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity","volume":"121","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib16","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib17","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ophtha.2012.05.027","article-title":"The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1)","volume":"119","author":"Chew","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib18","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1167\/iovs.13-11804","article-title":"Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 report number 2)","volume":"54","author":"Danis","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2020.09.025_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A\u00a0large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.oret.2020.09.025_bib20","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","article-title":"Risk of scar in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Daniel","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2013.02.012","article-title":"Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab","volume":"156","author":"Bloch","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2020.09.025_bib22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1167\/iovs.18-25189","article-title":"Identification and quantification of the angiofibrotic switch in neovascular AMD","volume":"60","author":"Roberts","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2020.09.025_bib23","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ophtha.2018.01.004","article-title":"Development and course of scars in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"125","author":"Daniel","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000002779","article-title":"Prevalence and risk factors for the development of physician-graded subretinal fibrosis in eyes treated for neovascular age-related macular degeneration","author":"Teo","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.oret.2020.09.025_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2020.03.031","article-title":"Spectral-domain OCT analysis of risk factors for macular atrophy development in the HARBOR study for neovascular age-related macular degeneration","author":"Sadda","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ophtha.2018.07.013","article-title":"Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial","volume":"126","author":"Bailey","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 years of Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jamaophthalmol.2015.4948","article-title":"Correlation of 3-dimensionally quantified intraretinal and subretinal fluid with visual acuity in neovascular age-related macular degeneration","volume":"134","author":"Waldstein","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2020.09.025_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2020.03.010","article-title":"Application of automated quantification of fluid volumes to anti-VEGF therapy of neovascular age-related macular degeneration","author":"Schmidt-Erfurth","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib30","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ophtha.2012.06.056","article-title":"Predictors of AMD treatment response","volume":"119","author":"Wickremasinghe","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib31","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/IAE.0000000000001736","article-title":"Predictors of one-year visual outcomes after anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration","volume":"38","author":"Kodjikian","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.oret.2020.09.025_bib32","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1167\/iovs.18-25628","article-title":"A\u00a0combination therapy targeting endoglin and VEGF-A prevents subretinal fibro-neovascularization caused by induced Muller cell disruption","volume":"59","author":"Shen","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2020.09.025_bib33","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib34","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ophtha.2018.11.036","article-title":"Characterization of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents","volume":"126","author":"Nguyen","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib36","article-title":"Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study","author":"Holz","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.oret.2020.09.025_bib37","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaophthalmol.2014.1019","article-title":"Sustained visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"132","author":"Ying","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2020.09.025_bib38","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","article-title":"Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials","volume":"118","author":"Rosenfeld","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.09.025_bib39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2019.10.007","article-title":"Ten-year treatment outcomes of neovascular age-related macular degeneration from two regions","volume":"210","author":"Gillies","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2020.09.025_bib40","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.oret.2019.06.002","article-title":"The evolution of fibrosis and atrophy and their relationship with visual outcomes in Asian persons with neovascular age-related macular degeneration","volume":"3","author":"Cheung","year":"2019","journal-title":"Ophthalmol Retina"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653020304085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653020304085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:28:20Z","timestamp":1762853300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653020304085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2468653020304085"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2020.09.025","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Principal Cause of Poor Visual Acuity after Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2020.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}